Pharmacokinetics and Tissue Distribution Study of Pinosylvin in Rats by Ultra-High-Performance Liquid Chromatography Coupled with Linear Trap Quadrupole Orbitrap Mass Spectrometry

Table 4

Stability of pinosylvin in rat plasma, urine, feces, and various tissue homogenates (n=5).

Bio-sample	Nominal concentration (ng/mL)	Autosampler (24 h, 7°C)		Three freeze/thaw cycles		Room temperature (12 h)		Long term (30 days,-80°C)
		Precision (%)	Accuracy (%)	Precision (%)	Accuracy (%)	Precision (%)	Accuracy (%)	Precision (%)	Accuracy (%)
Plasma	5.4	1.2	10.9	4.2	7.9	2.9	9.3	6	10
	135	6.4	-3.3	6.1	4.1	8.9	-3.5	9.5	-4.6
	540	8.4	0.9	9.8	0.8	8.7	4.1	6.2	1.6
Urine	1350	3.6	5	1.3	8	1.4	8.6	0.4	9.9
	5400	9.2	-1.4	5.5	-3.4	0.9	-4.7	3	-2.6
	54000	7.3	-6.8	1.6	-0.7	1.8	-6	7.3	-6.8
Feces	270	6.5	-4.4	7.8	-5.8	9.6	-3.3	12.9	8.5
	2700	2.1	-8.5	3.4	-3.2	2	7.8	2	2.7
	5400	3.8	0.7	4.7	-2.6	8.9	3.1	4.5	-1
Heart	540	1.5	9.2	4	8.3	4.7	7.7	2.6	5.4
	5400	8	-0.3	7.9	2.6	4.7	2.2	4.9	-9.6
	27000	9.6	2.1	9.1	5.7	0.5	8.7	2.3	8.2
Liver	2700	8.4	-9.6	8.4	6.8	9.6	5.2	7.2	2.8
	13500	9.7	-1.6	4	-4.9	8.3	8.7	9.2	4
	54000	6.8	-5.1	5.4	0.6	8.7	-8.1	9.4	-9.4
Spleen	270	2.4	14.7	1.6	15	1.9	17.5	1.8	16.7
	5400	7.7	2.5	4.9	4.2	6.1	-7.1	5.8	2.2
	13500	7.8	-7.5	9.2	-1.7	9.2	-7.7	6.6	-8.8
Lung	540	2.1	14.6	4.2	6	4	10.7	3.2	10.2
	2700	6.5	3.7	7.4	-5.2	4.1	11	9.5	7
	13500	9.8	2.6	6.7	4.9	6.2	5.2	9.5	8
Kidney	540	8.8	-9.1	7.2	-5.4	8.2	-6.5	9.7	1.3
	5400	9	-2.2	10.4	3	4.8	-2.7	10.8	-5.3
	13500	8	-0.3	8	-7	8.7	-1.5	9.4	1.5
Large intestine	2700	7.9	8.3	9.2	6.8	9.3	4.8	10.4	-5.4
	13500	9.5	-8.9	6.8	-8.9	3.9	-10.3	8.4	-9
	54000	8.6	5.7	8.2	8.1	7.1	8.1	7.9	7.6
Small intestine	5400	13	-2.5	8.9	-13	7.9	10.5	13.1	5.1
	108000	6.3	15.1	4.2	6.8	13.9	8.3	1.6	8.3
	216000	5.9	13.3	5	14.5	5	-4.7	4.1	-7.7
Stomach	13500	9.5	14.5	7.8	13.7	14.6	7.7	9.5	10.5
	216000	8.9	-13.7	13.3	-11.5	13.3	0.9	11.4	-0.9
	864000	13.3	-3	11.9	-9.4	11.9	-9.1	13.5	-12.2